Prognostic Factors in Breast Cancer; Many Identified; Examples: Node status Tumour size Histologic grade Estrogen receptor Progesterone receptor IGF-IR.

Slides:

Advertisements

Similar presentations

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.

Advertisements

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.

Cancer Genetics Is Cancer a Genetic Disease? Cancer is not a classic genetic disease, instead, Genetic background (set-up) has a definite role in cancer.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.

Transforming Growth Factor-Beta Receptor 2 TGF-β receptor 2

P73 Shatil Amin March 27 th Content I.Structure and Function II.Regulation III.Is it involved in human cancers?

Prepared by Dr. Ammar C. Al-Rikabi & Dr. Ghassan Zidan.

Emily Hodgson Hallmarks of Cancer Immunology Drugs Metastasis.

P53 has a key role in integrating the cellular responses (pink boxes) to different types of stress (blue boxes). Activation of p53 can result in a number.

Tumor genetics Minna Thullberg

Cell Cycle and Cancer. Cancer Terms Neoplasm – new, abnormal growth of cells Benign – not cancerous Malignant - cancerous Cancer – cellular growth disorder.

1. Cancer and the cell cycle

Metastatic Cancer – Gross Pathology Lymph node - metastasis from breastLiver – metastasis from lung Vertebral column – metastasis from prostate Mesentery.

1. p53 Structure, Function and Therapeutic Applications Provider: Dr.Davood Nourabadi(PhD,medical physiology) mdphysiology.persianblog.ir.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Functions of Onc-Gene Products: Growth Factor Receptors Signal Transduction, Nuclear Transcription Factors Folder Title: OncProteins Updated: April 20,

 Regulation of Cell Number and Cancer Cells Special Limited Edition Packet Tuesday, November 10,

Craig D. Woodworth, Evan Michael, Laura Smith, and Matthias Nees. Department of Biology, Clarkson University, Potsdam, NY, USA, and Department of Pediatric.

Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.

Cancer Accelerated Biology. Learning Objectives The different methods of diagnosing cancer. The difference between a malignant tumor and a benign tumor.

Neoplasia 4 Dr. Hiba Wazeer Al Zou’bi. 4- Nuclear Transcription Factors: DNA transcription regulated by genes e.g. MYC, MYB, JUN, FOS, REL oncogenes 

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,

CANCER MODULE Units 1.3, 2.2, 2.3, 2.4, 2.5. REGULATION OF THE CELL CYCLE Drivers Checkpoints Divide!!Don’t divide!!

Supp table 1: Gene sets differentially expressed in Angpt-1 high MDS samples No.Gene Set NameGenes 1KEGG_CELL_CYCLE cyclin-dependent kinase 1, E2F transcription.

Cell Growth & Division Control of Cell Cycle | Disruptions to Cell Cycle.

Chapter 9 Cell Cycle and Cancer. Figure 17-1 Molecular Biology of the Cell (© Garland Science 2008) Cell Cycle.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Lung Cancer Tumour Markers

Invasive skin carcinoma—Ras and α6β4 integrin lead the way

Combinatorial interactions of cyclins and cyclin-dependent kinases (cdks) during the cell cycle. Progression from G0 through the restriction point in G1.

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

Mouse Double Minute 2 (MDM2)

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Genetics In Breast Cancer

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

The protein products of tumor-suppressor genes often function in conserved signaling pathways with other tumor-suppressor gene and oncogene protein products.

Regulation of the Cell Cycle & Cancer

ד"ר אלה עברון אונקולוגיה ומכון השד אסף הרופא

Figure 1 Cellular processes involved in cancer development

The promise of cancer genetics

B lymphocytes produce antibodies.

Chapter 12: The Cell Cycle

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Figure 4 Possible combination therapies CDK4/6 inhibitors

The Cell Cycle and Understanding Cancer

Dan Gordon Gastroenterology Volume 114, Issue 4, (April 1998)

Figure 1 A schematic representation of the HER2 signalling pathway

BIOLOGY 12 Cancer.

Mechanisms of apoptosis and growth arrest by isothiocyanates.

Chapter 12: The Cell Cycle

Chapter 12: The Cell Cycle

Cell to Cell Communication

Treatment Overview: The Multidisciplinary Team

The promise of cancer genetics

Checkpoint blockade therapy resistance in Hodgkin's lymphoma

10.3 Regulating the Cell Cycle

AP Biology The Cell Cycle.

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

LEQ: Why is the eukaryotic cell cycle regulated?

Chapter 12: The Cell Cycle

Objectives: 1. Cancer and the cell cycle checkpoints, reqmts to advance oncogenes tumor suppressor genes 2. 6 Traits of cancerous cells 3. Facts on.

Chapter 12: The Cell Cycle

Phases of the Cell Cycle

Phases of the Cell Cycle

(Handling and Evaluation of Breast Cancer Biopsy)

Neoplasia lecture 7 Dr Heyam Awad FRCPath.

Invasive skin carcinoma—Ras and α6β4 integrin lead the way

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

Presentation transcript:

Prognostic Factors in Breast Cancer; Many Identified; Examples: Node status Tumour size Histologic grade Estrogen receptor Progesterone receptor IGF-IR Marrow micromets ErbB-2 expression EGF-R TP53 mutations Cathepsin D Telomerase activity PAI-1 level

ERBB2 GRB7 TNF-receptor-associated factor 4 TGFB1-induced anti-apoptotic factor 1 Cadherin 3 Laminin keratin 17 keratin 5 troponin I TGF beta 2 GRO1 oncogene, alpha CD36 antigen collagen glutathione peroxidase 3 plasma lipoprotein lipase integrin, alpha 7 retinol-binding protein 4 Putative G-coupled receptor Estrogen receptor trefoil factor 3 GATA-binding protein 3 X-box binding protein 1 LIV-1 NAT1 arylamine transferrin receptor p90 V-myb homolog integral membrane transporter hydrolase conjugase nucleolar protein p40 Nature 406: ,2000 PNAS 98: , 2001

”Survival or RFS ”endpoints” ”Metastatic potential” ”Therapy effect” ”Growth rate” Lymph node status TP53 Mutations

Cell cycle Cyclins ( cyc D) and a cdk (like cdk4/cdk6) complex Acting in different phases of the cycle Influenced by inhibitors (p16, p21, p27, p57) Amplifications – mutations Influenced by upstream GF / Oncogenes Some genes involved in cell cycle control (sometimes at G1 as well as G2) also involved in apoptosis (p53) Therapy effects; growth arrest / apoptosis poorly understood

X1 X2 X3 X4 Y2 Y1 Z1 Z2 Z3 Y11 Y21 Z11 Z21 Z31 D1 D12 D2 D21 D22 D23 D3 D31 G1 G2 G3 G11 G111 G21 G31

X1 X2 X3 X4 Y2 Y1 Z1 Z2 Z3 Y11 Y21 Z11 Z21 Z31 D1 D12 D2 D21 D22 D23 D3 D31 G1 G2 G3 G11 G111 G21 G31 Y1 Y2 Y3